Pathogenesis of varicose veins - Lessons from biomechanics;Pathogenese der varizenbildung - Lehren aus der biomechanik

Vasa - Journal of Vascular Diseases

Volumn 43, Issue 2, 2014, Pages 88-99

  Pfisterer, Larissa ^a   König, Gerd ^a   Hecker, Markus ^a   Korf, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Circumferential wall tension; Endothelial cells; Remodelling; Shear stress; Varicose veins; Vascular smooth muscle cells

Indexed keywords

CALCIUM ION; CD40 LIGAND; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR AP 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ABDOMINAL PRESSURE; ANGIOGENESIS; ARTERIOSCLEROSIS; BIOMECHANICS; BLOOD FLOW; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEMODYNAMICS; HUMAN; HYPERTENSION; INCIDENCE; NONHUMAN; PHYSICAL ACTIVITY; QUESTIONNAIRE; REVIEW; RISK FACTOR; SHEAR STRESS; SIGNAL TRANSDUCTION; VARICOSIS; VEIN DISEASE;

CIRCUMFERENTIAL WALL TENSION; ENDOTHELIAL CELLS; REMODELLING; SHEAR STRESS; VARICOSE VEINS; VASCULAR SMOOTH MUSCLE CELLS;

ANIMALS; BIOMECHANICAL PHENOMENA; CHRONIC DISEASE; DISEASE PROGRESSION; HEMODYNAMICS; HUMANS; MECHANOTRANSDUCTION, CELLULAR; RISK FACTORS; STRESS, MECHANICAL; VARICOSE VEINS; VEINS; VENOUS INSUFFICIENCY; VENOUS PRESSURE;

EID: 84896263794     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000335     Document Type: Review

References (89)

1. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005 Mar; 15(3): 175-84.
2. Raju S, Neglen P. Clinical practice. Chronic venous insufficiency and varicose veins. T e New England journal of medicine. 2009 May 28; 360(22): 2319-27.
3. Clarke GH, Vasdekis SN, Hobbs JT, Nicolaides AN. Venous wall function in the pathogenesis of varicose veins. Surgery. 1992 Apr; 111(4): 402-8.
4. Cooper DG, Hillman-Cooper CS, Barker SG, Hollingsworth SJ. Primary varicose veins: the sapheno-femoral junction, distribution of varicosities and patterns of incompetence. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery. 2003 Jan; 25(1): 53-9.
5. Ibrahim S, MacPherson DR, Gold-haber SZ. Chronic venous insufficiency: mechanisms and management. American heart journal. 1996 Oct; 132(4): 856-60.
6. Wali MA, Eid RA. Changes of elastic and collagen fibers in varicose veins. Int Angiol. 2002 Dec; 21(4): 337-43.
7. Somers P, Knaapen M. The histo-pathology of varicose vein disease. Angiology. 2006 Oct-Nov; 57(5): 546-55.
8. Sansilvestri-Morel P, Rupin A, Jais-son S, Fabiani JN, Verbeuren TJ, Vanhoutte PM. Synthesis of collagen is dysregulated in cultured f bro-blasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. Circulation. 2002 Jul 23; 106(4): 479-83.
9. Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg. 2009 Nov; 96(11): 1231-42.
10. Rafetto JD, Khalil RA. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology. 2008; 23(2): 85-98.
11. Burkitt D P, Townsend AJ, Patel K, Skaug K. Varicose veins in developing countries. Lancet. 1976 Jul 24; 2(7978): 202-3.
12. Lee AJ, Evans CJ, Allan PL, Ruck-ley C V, Fowkes FG. Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. J Clin Epidemiol. 2003 Feb; 56(2): 171-9.
13. Mulvany MJ. Small artery remodeling in hypertension. Curr Hyper-tens Rep. 2002 Feb; 4(1): 49-55.
14. Mulvany MJ. Small artery remodeling and significance in the development of hypertension. News Physiol Sci. 2002 Jun; 17: 105-9.
15. Korf T, Aufgebauer K, Hecker M. Cyclic stretch controls the expression of CD40 in endothelial cells by changing their transforming growth factor-beta1 response. Circulation. 2007 Nov 13; 116(20): 2288-97.
16. Atta HM. Varicose veins: role of mechanotransduction of venous hypertension. Int J Vasc Med. 2012; 2012: 538627.
17. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994 Apr 28; 368(6474): 850-3.
18. Murad F, Rapoport RM, Fiscus R. Role of cyclic-GMP in relaxations of vascular smooth muscle. J Car-diovasc Pharmacol. 1985; 7 Suppl 3: 111-8.
19. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Upreg-ulation of TRAF- 3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest. 2001 Nov; 108(10): 1451-8.
20. Seidel CL, LaRochelle J. Venous and arterial endothelia: Different dilator abilities in dog vessels. Circ Res. 1987 Apr; 60(4): 626-30.
21. Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med. 2006 Apr; 259(4): 381-92.
22. Lehoux S. Redox signalling in vascular responses to shear and stretch. Cardiovasc Res. 2006 Jul 15; 71(2): 269-79.
23. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012 Jul 15; 95(2): 194-204.
24. Hahn C, Schwartz MA. Mechano-transduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol. 2009 Jan; 10(1): 53-62.
25. Feldner A, Otto H, Rewerk S, Hecker M, Korf T. Experimental hypertension triggers varicosis-like maladaptive venous remodeling through activator protein- 1. FASEB J. 2011 Oct; 25(10): 3613-21.
26. Birukov KG. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal. 2009 Jul; 11(7): 1651-67.
27. Patel R, Cardneau JD, Colles SM, Graham LM. Synthetic smooth muscle cell phenotype is associated with increased nicotinamide adenine dinucleotide phosphate oxidase activity: effect on collagen secretion. J Vasc Surg. 2006 Feb; 43(2): 364-71.
28. Su B, Mitra S, Gregg H, Flavahan S, Chotani MA, Clark KR, et al. Re-dox regulation of vascular smooth muscle cell differentiation. Circ Res. 2001 Jul 6; 89(1): 39-46.
29. Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal. 2008 Jun; 10(6): 1045-59.
30. Cai Y, Knight WE, Guo S, Li JD, Knight PA, Yan C. Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. J Pharmacol Exp T er. 2012 Nov; 343(2): 479-88.
31. Stojakovic M, Krzesz R, Wagner AH, Hecker M. CD154-stimulat-ed GM-CSF release by vascular smooth muscle cells elicits mono-cyte activation-role in atherogen-esis. J Mol Med (Berl). 2007 Nov; 85(11): 1229-38.
32. Woodside KJ, Hu M, Burke A, Murakami M, Pounds LL, Killewich LA, et al. Morphologic characteristics of varicose veins: possible role of metalloproteinases. Journal of vascular surgery. 2003 Jul; 38(1): 162-9.
33. Aunapuu M, Arend A. Histopatho-logical changes and expression of adhesion molecules and laminin in varicose veins. VASA Zeitschrif fur Gefasskrankheiten. 2005 Aug; 34(3): 170-5.
34. Gomez I, Benyahia C, Le Dall J, Payre C, Louedec L, Leseche G, et al. Absence of inflammatory conditions in human varicose saphe-nous veins. Inflammation research: official journal of the European Histamine Research Society [et al. 2013 Mar; 62(3): 299-308.
35. Ghaderian SM, Lindsey NJ, Graham AM, Homer-Vanniasinkam S, Akbarzadeh Najar R. Pathogenic mechanisms in varicose vein disease: the role of hypoxia and inflammation. Pathology. 2010; 42(5): 446-53.
36. Hahn TL, Whitfeld R, Salter J, Granger DN, Unthank JL, Lalka SG. Evaluation of the role of intercellular adhesion molecule 1 in a rodent model of chronic venous hypertension. T e Journal of surgical research. 2000 Feb; 88(2): 150-4.
37. Hahn TL, Unthank JL, Lalka SG. Increased hindlimb leukocyte concentration in a chronic rodent model of venous hypertension. The Journal of surgical research. 1999 Jan; 81(1): 38-41.
38. Lalka SG, Unthank JL, Nixon JC. Elevated cutaneous leukocyte concentration in a rodent model of acute venous hypertension. T e Journal of surgical research. 1998 Jan; 74(1): 59-63.
39. Meng X, Mavromatis K, Galis ZS. Mechanical stretching of human saphenous vein graf s induces expression and activation of matrix-degrading enzymes associated with vascular tissue injury and repair. Exp Mol Pathol. 1999 Aug; 66(3): 227-37.
40. Jacob MP, Cazaubon M, Scemama A, Prie D, Blanchet F, Guillin MC, et al. Plasma matrix metalloprotein-ase- 9 as a marker of blood stasis in varicose veins. Circulation. 2002 Jul 30; 106(5): 535-8.
41. 2+] e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010 Apr; 159(2): 755-64.
42. Sansilvestri-Morel P, Rupin A, Jul-lien ND, Lembrez N, Mestries-Du-bois P, Fabiani JN, et al. Decreased production of collagen Type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP- 3. J Vasc Res. 2005 Sep-Oct; 42(5): 388-98.
43. Sansilvestri-Morel P, Rupin A, Badier-Commander C, Kern P, Fabiani JN, Verbeuren TJ, et al. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res. 2001 Nov-Dec; 38(6): 560-8.
44. Ward MR, Pasterkamp G, Yeung AC, Borst C. Arterial remodeling. Mechanisms and clinical implications. Circulation. 2000 Sep 5; 102(10): 1186-91.
45. Unthank JL, Nixon JC, Dalsing MC. Inhibition of NO synthase prevents acute collateral artery dilation in the rat hindlimb. The Journal of surgical research. 1996 Mar; 61(2): 463-8.
46. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med. 2006 Jan-Mar; 10(1): 45-55.
47. Heil M, Schaper W. Inf uence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res. 2004 Sep 3; 95(5): 449-58.
48. Unthank JL, Sheridan KM, Dals-ing MC. Collateral growth in the peripheral circulation: a review. Vascular and endovascular surgery. 2004 Jul-Aug; 38(4): 291-313.
49. Unthank JL, Fath SW, Burkhart HM, Miller SC, Dalsing MC. Wall remodeling during luminal expansion of mesenteric arterial collaterals in the rat. Circulation research. 1996 Nov; 79(5): 1015-23.
50. Demicheva E, Hecker M, Korf T. Stretch-induced activation of the transcription factor activator protein- 1 controls monocyte che-moattractant protein- 1 expression during arteriogenesis. Circ Res. 2008 Aug 29; 103(5): 477-84.
51. Cai W, Vosschulte R, Afsah-Hedjri A, Koltai S, Kocsis E, Scholz D, et al. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. J Mol Cell Cardiol. 2000 Jun; 32(6): 997-1011.
52. Shyy J Y, Lin MC, Han J, Lu Y, Petrime M, Chien S. The cis-acting phorbol ester 12-O-tetradecanoylphorbol 13-acetate-responsive element is involved in shear stress-induced monocyte chemotactic protein 1 gene expression. Proc Natl Acad Sci U S A. 1995 Aug 15; 92(17): 8069-73.
53. Heil M, Ziegelhoefer T, Wagner S, Fernandez B, Helisch A, Martin S, et al. Collateral artery growth (arte-riogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor- 2. Circ Res. 2004 Mar 19; 94(5): 671-7.
54. Schepers A, Eefing D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, et al. Anti-MCP- 1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graf thickening both in vitro and in vivo. Arterioscler T romb Vasc Biol. 2006 Sep; 26(9): 2063-9.
55. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kubler W, et al. Monocyte chemoattractant pro-tein- 1 induces proliferation and interleukin- 6 production in human smooth muscle cells by Differential activation of nuclear factor-kappaB and activator protein- 1. Arterio-scler Thromb Vasc Biol. 2002 Jun 1; 22(6): 914-20.
56. Rabe E, Pannier-Fischer F, Bromen K, Schuldt K, Stang A, Poncar C, et al. Bonn Vein Study by the German Society of Phlebology-Epide-miological study to investigate the prevalence and severity of chronic venous disorders in the urban and rural residential populations. Phle-bologie. 2003 Mar; 32(1): 1-14.
57. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. Journal of epidemiology and community health. 1999 Mar; 53(3): 149-53.
58. Robertson L, Evans C, Fowkes FG. Epidemiology of chronic venous disease. Phlebology/Venous Forum of the Royal Society of Medicine. 2008; 23(3): 103-11.
59. Clark A, Harvey I, Fowkes FG. Epidemiology and risk factors for varicose veins among older people: cross-sectional population study in the UK. Phlebology. 2010 Oct; 25(5): 236-40.
60. Scott TE, LaMorte W W, Gorin DR, Menzoian JO. Risk factors for chronic venous insufficiency: a dual case-control study. Journal of vascular surgery. 1995 Nov; 22(5): 622-8.
61. Iannuzzi A, Panico S, Ciardullo AV, Bellati C, Ciof V, Iannuzzo G, et al. Varicose veins of the lower limbs and venous capacitance in post-menopausal women: relationship with obesity. J Vasc Surg. 2002 Nov; 36(5): 965-8.
62. van Rij AM, De Alwis CS, Jiang P, Christie RA, Hill GB, Dutton SJ, et al. Obesity and impaired venous function. Eur J Vasc Endovasc Surg. 2008 Jun; 35(6): 739-44.
63. Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med. 1988 Mar-Apr; 4(2): 96-101.
64. Seidell JC, Bakx KC, Deurenberg P, van den Hoogen HJ, Hautvast JG, Stijnen T. Overweight and chronic illness-a retrospective cohort study, with a follow-up of 6-17 years, in men and women of initially 20-50 years of age. J Chronic Dis. 1986; 39(8): 585-93.
65. Kroger K, Ose C, Rudofsky G, Ro-esener J, Weiland D, Hirche H. Peripheral veins: influence of gender, body mass index, age and varicose veins on cross-sectional area. Vasc Med. 2003 Nov; 8(4): 249-55.
66. Laurikka JO, Sisto T, Tarkka MR, Auvinen O, Hakama M. Risk indicators for varicose veins in forty-to sixty-year-olds in the Tampere varicose vein study. World J Surg. 2002 Jun; 26(6): 648-51.
67. Eberhardt RT, Rafetto JD. Chronic venous insufficiency. Circulation. 2005 May 10; 111(18): 2398-409.
68. Erdogan T, Cetin M, Kocaman SA, Durakoglugil ME, Ergul E, Canga A. Aortic valve sclerosis is a high predictive marker of systemic endo-thelial dysfunction in hypertensive patients. Herz. 2013 Feb 13.
69. Katsi V, Marketou M, Kallistratos MS, Makris T, Manolis AJ, Tou-soulis D, et al. Aortic valve stenosis and arterial hypertension: a synopsis in 2013. Curr Hypertens Rep. 2013 Aug; 15(4): 298-303.
70. Rafetto JD, Qiao X, Koledova V V, Khalil RA. Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins. J Vasc Surg. 2008 Aug; 48(2): 447-56.
71. Ströbel P. Ätiologie der Varikose. T Noppeney HN, editor. Heidelberg: Springer; 2010.
72. Stansby G. Women, pregnancy, and varicose veins. Lancet. 2000 Apr 1; 355(9210): 1117-8.
73. Matrai M, Mericli M, Nadasy GL, Szekeres M, Varbiro S, Banhidy F, et al. Gender differences in biome-chanical properties of intramural coronary resistance arteries of rats, an in vitro microarteriographic study. J Biomech. 2007; 40(5): 1024-30.
74. Faubel R, Schäfer I, Augustin M, Bruning G. Langzeitergebnisse und Analysen von Zusammenhän-gen 5 Jahre nach Varizenstripping. Phlebologie. 2010; 39(5): 263-9.
75. Pares JO, Juan J, Tellez R, Mata A, Moreno C, Quer FX, et al. Varicose vein surgery: stripping versus the CHIVA method: a randomized controlled trial. Ann Surg. 2010 Apr; 251(4): 624-31.
76. Carandina S, Mari C, De Palma M, Marcellino MG, Cisno C, Legnaro A, et al. Varicose vein stripping vs haemodynamic correction (CHI-VA): a long term randomised trial. Eur J Vasc Endovasc Surg. 2008 Feb; 35(2): 230-7.
77. Glass GM. Neovascularization in recurrence of varices of the great sa-phenous vein in the groin: phlebog-raphy. Angiology. 1988 Jul; 39(7 Pt 1): 577-82.
78. Winterborn RJ, Earnshaw JJ. Cros-sectomy and great saphenous vein stripping. J Cardiovasc Surg (Torino). 2006 Feb; 47(1): 19-33.
79. Rewerk S, Noppeney T, Winkler M, Willeke F, Duczek C, Meyer A, et al. Pathogenese der Primär- und Rezidivvarikosis an der Magna-Krosse. Phlebologie. 2007; 36(3): 137-42.
80. Helisch A, Schaper W. Arteriogen-esis: the development and growth of collateral arteries. Microcirculation. 2003 Jan; 10(1): 83-97.
81. Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator-Schmitt M, et al. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor an-giogenesis. EMBO J. 2007 Feb 7; 26(3): 710-9.
82. Tsurumi Y, Murohara T, Krasin-ski K, Chen D, Witzenbichler B, Kearney M, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med. 1997 Aug; 3(8): 879-86.
83. Noyes LD, Rice JC, Kerstein MD. Hemodynamic assessment of high-compression hosiery in chronic venous disease. Surgery. 1987 Nov; 102(5): 813-5.
84. Amsler F, Blattler W. Compression therapy for occupational leg symptoms and chronic venous disorders-a meta-analysis of randomised controlled trials. Eur J Vasc Endovasc Surg. 2008 Mar; 35(3): 366-72.
85. Busse R, Fleming I. Pulsatile stretch and shear stress: physical stimuli determining the production of endothe-lium-derived relaxing factors. J Vasc Res. 1998 Mar-Apr; 35(2): 73-84.
86. Taniyama Y, Griendling KK. Reactive oxygen species in the vascula-ture: molecular and cellular mechanisms. Hypertension. 2003 Dec; 42(6): 1075-81.
87. Krzysciak W, Kozka M. Generation of reactive oxygen species by a sufficient, insufficient and varicose vein wall. Acta Biochim Pol. 2011; 58(1): 89-94.
88. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, et al. Comparison of Pycnogenol and Daf on in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost. 2006 Apr; 12(2): 205-12.
89. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares M P, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterios cler Thromb Vasc Biol. 2003 Jan 1; 23(1): 58-63.